Repare Therapeutics Inc. Stock Price, News & Analysis

Repare Therapeutics Inc. (Nasdaq: RPTX) announced comprehensive Phase 1 monotherapy data from its ongoing Phase 1/2 TRESR trial for RP-3500, an ATR inhibitor, to be presented at the 2022 AACR Annual Meeting in New Orleans from April 8-13, 2022. An oral presentation is scheduled for April 11, 2022, at 3:05 PM CT, led by Dr. Timothy Yap. The company will host a conference call to discuss these findings on the same day at 6:30 PM ET. Repare aims to highlight RP-3500's therapeutic potential and ongoing development plans.

Repare Therapeutics (NASDAQ: RPTX) announced that it will present clinical data from its Phase 1/2 TRESR trial of RP-3500 at the upcoming 2022 AACR Annual Meeting in New Orleans. The oral presentation, focusing on genomic determinants of response to RP-3500 in patients with DNA damage repair mutant tumors, is scheduled for April 11, 2022. Additionally, a poster will be presented on the SNiPDx panel, aimed at detecting DNA repair gene losses in tumor samples, on April 12, 2022. Repare’s SNIPRx® platform supports its precision therapeutics development.

Repare Therapeutics Inc. announced positive findings from its Phase 1/2 TRESR clinical trial of RP-3500, a selective ATR inhibitor for treating solid tumors. Data presented at the ESMO TAT Congress confirmed that RP-3500 is well tolerated, with a recommended Phase 2 dose of 160mg 3 days on/4 days off. Anemia was the primary reported toxicity, impacting less than 25% of patients.

The company plans to share updated data from 120 patients in the first half of the year, reinforcing expectations for the therapeutic potential of RP-3500.

Repare Therapeutics Inc. (RPTX) reported its financial results for Q4 and full year 2021, highlighting key advancements in its precision oncology pipeline. Notable progress includes the initiation of the RP-6306 program and the RP-3500 Phase 2 trial for solid tumors. By December 31, 2021, cash reserves stood at $341.9 million, sufficient for operations through 2023. R&D expenses surged to $90 million, reflecting increased development costs. The net loss was $106.9 million, or $2.83 per share, compared to $53.4 million, or $2.66 per share in 2020.

Repare Therapeutics Inc. (NASDAQ: RPTX) announced participation in two virtual investor conferences in February 2022. The Guggenheim Oncology Conference is scheduled for February 10, 2022 at 2:00 p.m. ET, while the 11th Annual SVB Leerink Global Healthcare Conference will take place on February 18, 2022 at 3:00 p.m. ET. Live webcasts for both presentations will be available on the Company's website, with archiving for 90 days. Repare specializes in precision oncology, utilizing its SNIPRx® platform for targeted cancer therapies.

Repare Therapeutics (RPTX) provided a corporate update, highlighting significant advancements in 2021 and expectations for 2022. The company reported positive Phase 1 data for RP-3500 and initiated patient enrollment for combination trials. Key milestones include the upcoming Phase 2 TRESR trial for RP-3500, data releases for RP-3500 and RP-6306, and IND-enabling studies for a Polθ inhibitor. Repare ended Q3 2021 with approximately $268.2 million in cash, facilitating operations through 2023. The company will present at the J.P. Morgan Healthcare Conference on January 12, 2022.

Repare Therapeutics has appointed Philip Herman as its EVP Commercial & New Product Development, bringing over 20 years of experience in the pharmaceutical and biotech industries. The company is focused on advancing its lead products, RP-3500 and RP-6306, in the precision oncology space. Herman's prior role as CCO at Y-mAbs Therapeutics included launching DANYELZA®. The company aims for a significant transition from clinical stages to commercialization in 2022, enhancing their integrated product development and launch strategies.

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced that Lloyd M. Segal, CEO, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 3:45 p.m. ET. The presentation will be accessible via the Company's website, with a replay available for 30 days. Repare's innovative Synthetic Lethality approach aims to develop targeted cancer therapies, including lead candidate RP-3500, currently in Phase 1/2 clinical development.

Repare Therapeutics (NASDAQ: RPTX) has commenced its Phase 1 clinical trial for RP-6306, a pioneering small molecule targeting PKMYT1, combined with gemcitabine for treating advanced solid tumors. The trial, named MAGNETIC, aims to dose approximately 104 patients selected based on genomic alterations. The primary goals include determining the maximum tolerated dose and evaluating preliminary anti-tumor activity. This milestone follows ongoing developments in Repare's precision oncology pipeline, which features several innovative therapeutic candidates.